Women's Hormone Replacement Therapy: Estrogen, Progesterone, and Testosterone — Delivery Methods, Who Benefits, and When

Women's hormone replacement therapy gets discussed as a single decision — HRT, yes or no — when it's really three separate hormones, each with its own job, its own delivery-method tradeoffs, and its own evidence base. Estrogen, progesterone, and testosterone all show up in a well-designed HRT regimen, but they're not interchangeable, and lumping them together is where a lot of confusion starts. Estrogen: The Core Therapy, and Why Delivery Method Matters Enormously Estrogen is the primary hormone addressing the classic menopausal symptom cluster — hot flashes, night sweats, vaginal dryness, and the bone density protection covered in more depth in our companion article on the Women's Health Initiative. But how estrogen gets into your body changes its risk profile more than almost any other variable in this entire conversation. According to PubMed, a case-control study specifically comparing routes of estrogen administration found oral estrogen was associated with a substantially elevated risk of venous thromboembolism (blood clots) compared to non-users (odds ratio 4.5), while transdermal estrogen showed no significant increase in risk at all (odds ratio 1.2) ([Canonico et al., Journal of Clinical Endocrinology & Metabolism, 2008, PMID: 18628519](https://doi.org/10.1210/jc.2008-0450)). The mechanism is the same first-pass liver metabolism issue that shows up repeatedly across hormone therapy topics on this site: oral estrogen gets processed through the liver before reaching systemic circulation, which increases production of clotting factors in a way transdermal delivery (patch, gel, or spray, absorbed directly into the bloodstream through skin) simply doesn't trigger to the same degree. This is a genuinely significant, actionable distinction — the clotting risk most people associate with "hormone therapy" as a blanket category is substantially route-dependent, not an unavoidable property of estrogen itself. Age and Timing: Why This Isn't a Simple Yes/No According to PubMed, a comprehensive Cochrane systematic review pooling data from over 40,000 women found that the risk profile of hormone therapy changes meaningfully depending on age and time since menopause ([Marjoribanks et al., Cochrane Database of Systematic Reviews, 2017, PMID: 28093732](https://doi.org/10.1002/14651858.CD004143.pub5)). In women aged 50-59 specifically — the population most likely to actually be considering HRT for vasomotor symptoms — the only significantly increased risk identified was venous thromboembolism with combined continuous therapy, and even that absolute risk remained low, under 1 in 500. The review also found genuinely strong evidence of benefit for fracture prevention with long-term use, one of the few outcomes with that level of confidence behind it. This lines up directly with the "timing hypothesis" covered in more depth in our WHI article: the original data driving decades of fear came primarily from women with an average age over 60, often more than a decade past menopause onset — a meaningfully different population and risk profile than the women most commonly starting therapy today, closer to the menopause transition itself. Progesterone: Not Optional If You Have a Uterus, and Not All Progestogens Are Equal Any woman with a uterus taking estrogen needs a progestogen alongside it — without it, estrogen alone drives excessive growth of the uterine lining (endometrial hyperplasia), a well-documented and serious risk. But "progestogen" is a broad category covering genuinely different molecules, and the differences matter more than the shared category name suggests. According to PubMed, the large French E3N cohort study, following over 80,000 postmenopausal women for a mean of 8 years, found that combined estrogen plus micronized progesterone was not significantly associated with increased breast cancer risk, and estrogen plus dydrogesterone showed a more limited risk increase (specifically for lobular carcinoma) — while estrogen combined with other synthetic progestins showed significant increases in risk across multiple cancer subtypes, including a notably higher relative risk (2.6) for estrogen-receptor-positive, progesterone-receptor-negative tumors specifically ([Fournier et al., Journal of Clinical Oncology, 2008, PMID: 18323549](https://doi.org/10.1200/JCO.2007.13.4338)). This is one of the more important, underappreciated findings in the entire HRT conversation: the choice of which progestogen accompanies estrogen appears to meaningfully change the breast cancer risk profile, not just the endometrial protection it provides. Progesterone also has a genuine secondary benefit worth knowing about specifically: sleep. According to PubMed, a systematic review and meta-analysis of hormone therapy regimens and sleep quality found that combined estrogen and progesterone improved sleep disturbance more than estrogen alone, with estrogen plus micronized progesterone specifically identified as beneficial — and the same analysis found transdermal estrogen delivery outperformed oral for sleep outcomes as well ([Pan et al., Menopause, 2022, PMID: 35102100](https://doi.org/10.1097/GME.0000000000001945)). This is part of why oral micronized progesterone is commonly dosed at bedtime in clinical practice — beyond endometrial protection, it has a real, independently useful sedating effect for many women. For women who can't or don't want to take estrogen but are seeking symptom relief, progestin-only therapy has more limited support. According to PubMed, a systematic review of seven randomized trials found inconsistent results for progestin monotherapy on vasomotor symptoms — the largest trial using oral micronized progesterone alone did show meaningful improvement over placebo, but a comparably sized transdermal progesterone trial showed none, and no trial demonstrated improvement in mood symptoms specifically ([Dolitsky et al., Menopause, 2020, PMID: 33109992](https://doi.org/10.1097/GME.0000000000001676)). Progesterone alone is a reasonable option for specific situations, but it's clearly a different, less robust therapy than the combined estrogen-plus-progesterone approach. Testosterone in Women: Real Benefit, Genuinely Under-Prescribed Testosterone is the most under-discussed piece of women's HRT, and also the one where blood level monitoring matters most directly. According to PubMed, the International Society for the Study of Women's Sexual Health's clinical practice guideline — built on the broader Global Consensus Position Statement — recommends systemic transdermal testosterone specifically for postmenopausal women with hypoactive sexual desire disorder (HSDD) not primarily explained by relationship or mental health factors, citing moderate therapeutic benefit and no serious adverse events at physiologic doses in the available safety data ([Parish et al., Journal of Sexual Medicine, 2021, PMID: 33814355](https://doi.org/10.1016/j.jsxm.2020.10.009)). The blood level guidance here is specific and important: a total testosterone level should not be used to diagnose HSDD in the first place, but it is essential as a baseline before starting therapy and for ongoing monitoring, with the explicit goal of keeping levels within the normal premenopausal physiologic range — not pushing beyond it. The guideline is also direct about a real access problem: no testosterone product is specifically approved for women by most regulatory agencies (including the U.S.), meaning treatment currently relies on cautious off-label dosing of male-formulated transdermal products, carefully adjusted downward. The guideline explicitly cannot recommend compounded testosterone products, citing insufficient efficacy and safety data behind them specifically — a meaningful distinction from the regulated, government-approved formulations used off-label. This creates a real, practical monitoring requirement that doesn't exist in the same way for estrogen: because women's normal testosterone range is a fraction of the male range, and because off-label dosing of male products creates real risk of overshooting into supraphysiologic (androgenic) territory, testosterone therapy in women specifically requires tracking blood levels against signs of androgen excess (acne, unwanted hair growth, voice changes) in a way that estrogen therapy, more commonly guided by symptoms, does not. Putting the Three Together A woman with a uterus starting HRT for classic menopausal symptoms in her 50s, close to menopause onset, represents the population with the most favorable benefit-to-risk ratio across all three hormones. For her: transdermal estrogen carries meaningfully lower clotting risk than oral. Micronized progesterone (rather than older synthetic progestins) appears to carry a more favorable breast cancer risk profile alongside estrogen, plus a genuine sleep benefit when dosed at night. And if low libido persists despite adequate estrogen and life-context factors being addressed, testosterone — carefully monitored against the normal female physiologic range, not simply added at a male-typical dose — has real, guideline-backed support specifically for HSDD. The Bottom Line Women's HRT isn't a single yes/no decision — it's three hormones, each solving a different problem, each with delivery-method choices that measurably change the risk profile. Transdermal estrogen carries a better-documented safety record than oral for clotting risk. Progesterone type (micronized vs. older synthetic progestins) appears to matter for breast cancer risk, not just endometrial protection, and carries a real independent sleep benefit. Testosterone has genuine, guideline-supported benefit for a specific, common problem (HSDD) but requires the kind of blood-level monitoring that estrogen therapy generally doesn't. And the age and timing question isn't incidental — the research consistently shows the most favorable benefit-to-risk ratio in women closer to menopause onset, which is exactly the population most commonly considering this decision in the first place.